Quality of life in immune thrombocytopenia following treatment

Objective To determine the impact of therapy on the reported health-related quality of life (HRQoL) in children with primary immune thrombocytopenia (ITP) using the Kids ITP tool (KIT). Design Secondary data analysis of the international and North American KIT validation studies. Results 217 childre...

Full description

Saved in:
Bibliographic Details
Published in:Archives of disease in childhood 2013-11, Vol.98 (11), p.895-897
Main Authors: Grainger, John D, Young, Nancy L, Blanchette, Victor S, Klaassen, Robert J
Format: Article
Language:English
Subjects:
Adolescent
Age
Analysis
Biological and medical sciences
Care and treatment
Child
Child, Preschool
Children & youth
Demographic aspects
Diagnosis
Evaluation
Families & family life
Female
General aspects
General Paediatrics
Glucocorticoids - adverse effects
Glucocorticoids - therapeutic use
Haematology
Hematologic and hematopoietic diseases
Humans
Immunoglobulins, Intravenous - therapeutic use
Individualized Transition Plans
Isoantibodies - adverse effects
Isoantibodies - therapeutic use
ITP
Male
Medical sciences
Miscellaneous
Mortality
Observation
Outcome Measures
Parents
Patient care
Patients
Physicians
Platelet diseases and coagulopathies
Practice
Prednisone - adverse effects
Prednisone - therapeutic use
Prevention and actions
Psychometrics
Public health. Hygiene
Public health. Hygiene-occupational medicine
Purpura, Thrombocytopenic, Idiopathic - drug therapy
Purpura, Thrombocytopenic, Idiopathic - rehabilitation
Quality of Life
Rho(D) Immune Globulin
Severity of Illness Index
Statistical Significance
Studies
Thrombocytopenia
Treatment Outcome
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Objective To determine the impact of therapy on the reported health-related quality of life (HRQoL) in children with primary immune thrombocytopenia (ITP) using the Kids ITP tool (KIT). Design Secondary data analysis of the international and North American KIT validation studies. Results 217 children from 6 countries participated in the two studies. The majority of treatments occurred in children with newly diagnosed ITP. There was no statistical difference in age, platelet count and bleeding severity at presentation in those who physicians chose to treat or observe. Self-reported KIT scores did not differ between the two groups. The KIT parent-proxy scores were significantly worse for newly diagnosed children receiving treatment, especially following prednisone. Conclusions Treatment of ITP does not improve, and may worsen, the HRQoL of children with ITP as measured using the KIT.
ISSN:0003-9888
1468-2044
DOI:10.1136/archdischild-2013-303784